<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239758</url>
  </required_header>
  <id_info>
    <org_study_id>A031-06</org_study_id>
    <nct_id>NCT01239758</nct_id>
  </id_info>
  <brief_title>Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy</brief_title>
  <official_title>An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of ACE-031 (ActRIIB-IgG1) in Subjects With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acceleron Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acceleron Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term safety and tolerability of ACE-031 administration in subjects with
      Duchenne muscular dystrophy (DMD) who participated in Study A031-03. [Note: This study was
      terminated based on preliminary safety data. Pending further analysis of safety data and
      discussion with health authorities, a new ACE-031 trial will be planned.]
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was terminated based on preliminary safety data.
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events.</measure>
    <time_frame>From treatment initiation to End-of-Study Visit, approximately 24 weeks later.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in laboratory parameters and vital signs.</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in total lean body mass by DXA scan.</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in total body and lumbar spine bone mineral density by DXA scan.</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in muscle strength score by hand-held myometry.</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in distance traveled in 6 minutes (standardized 6-Minute-Walk Test).</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in time to travel 10 meters (standardized 10-Meter-Walk/Run test).</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function tests.</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>ACE-031 (Extension of cohort 1 from core study, A031-03)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE-031 (Extension of cohort 2 from core study, A031-03)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE-031 (Extension of cohort 3 from core study, A031-03)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACE-031 (Extension of cohort 1 from core study, A031-03)</intervention_name>
    <description>ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.</description>
    <arm_group_label>ACE-031 (Extension of cohort 1 from core study, A031-03)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACE-031 (Extension of cohort 2 from core study, A031-03)</intervention_name>
    <description>Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.</description>
    <arm_group_label>ACE-031 (Extension of cohort 2 from core study, A031-03)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACE-031 (Extension of cohort 3 from core study, A031-03)</intervention_name>
    <description>Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.</description>
    <arm_group_label>ACE-031 (Extension of cohort 3 from core study, A031-03)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of participation in Study A031-03 and Investigator approval

          -  Continuation of corticosteroid therapy at the same absolute dose and schedule as on
             Study A031-03

        Exclusion Criteria:

          -  Participation in any other therapeutic clinical trial

          -  Plans to have surgery during the course of the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Acceleron Investigative Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acceleron Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acceleron Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acceleron Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <disposition_first_submitted>January 24, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 30, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 1, 2013</disposition_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

